Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATM-guided individualized dosing of vancomycin for gram-positive bacterial infections
ChiCTR2100046718Phase 4Recruiting
- Sponsor
- Huashan Hospital
- Start
- May 2021
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vancomycin in Gram-positive bacterial infection, Staphylococcus aureus infection, coagulase-negative staphylococcal infection (CoNS) and 13 more, sponsored by Huashan Hospital. Primary endpoint: Acute kidney injury incidence. Started May 2021; status: recruiting.
02
Drugs
vancomycin
03
Conditions
Gram-positive bacterial infectionStaphylococcus aureus infectioncoagulase-negative staphylococcal infection (CoNS)enterococcal infectionendocarditis (IE)
Beyond the preview
Go deeper on ChiCTR2100046718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046718.